Welcome
Support Centre
25 April 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Multinational randomised controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritis
ISRCTN ISRCTN25142273
DOI 10.1186/ISRCTN25142273
ClinicalTrials.gov identifier
EudraCT number
Public title Multinational randomised controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritis
Scientific title
Acronym N/A
Serial number at source 025
Study hypothesis Not provided at time of registration
Lay summary Not provided at time of registration
Ethics approval Each site received the approval of its Ethics Review Committee or Institutional Review Board to perform the study.
Study design Randomised controlled trial
Countries of recruitment Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Costa Rica, France, Germany, Greece, Hong Kong, Israel, Italy, Lithuania, Mexico, New Zealand, Peru, Romania, Singapore, Slovenia, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States of America, Venezuela
Disease/condition/study domain Rheumatoid arthritis
Participants - inclusion criteria 1. Patients with rheumatoid arthritis
2. Aged greater than or equal to 18 years
Participants - exclusion criteria Does not match inclusion criteria
Anticipated start date 01/11/1999
Anticipated end date 01/06/2000
Status of trial Completed
Patient information material
Target number of participants 891
Interventions 1. Etoricoxib 90 mg once daily, naproxen 500 mg twice daily
2. Placebo for 12 weeks
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Merck & Co Inc (USA)
Trial website
Publications 2002 results in http://www.ncbi.nlm.nih.gov/pubmed/12033987
Contact name Mr  Sean  Curtis
  Address Merck & Co Inc
126 E Lincoln Avenue
  City/town Rahway
  Zip/Postcode NJ 07065
  Country United States of America
Sponsor Merck & Co Inc (USA)
  Address 126 E Lincoln Avenue
  City/town Rahway
  Zip/Postcode NJ 07065
  Country United States of America
  Sponsor website: http://www.merck.com
Date applied 09/05/2002
Last edited 15/11/2013
Date ISRCTN assigned 09/05/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.